Oxaliplatin Accord Healthcare

Oxaliplatin, the active ingredient in Oxaliplatin Accord Healthcare, is a platinum-based antineoplastic agent presented as a sterile powder for intravenous infusion use. It treats colorectal cancer and other solid tumours in adult patients. GNH USA supplies Oxaliplatin Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Oxaliplatin Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin is a platinum‑based chemotherapy drug that interferes with DNA replication in several cancer types.

- Colorectal cancer: improves the efficacy of combination regimens and helps achieve tumour shrinkage. - Gastric cancer: used as part of multimodal treatment protocols. - Pancreatic cancer: contributes to disease control when combined with other agents. - Ovarian cancer: employed in platinum‑sensitive treatment strategies. - Esophageal cancer: added to multidrug regimens to enhance response rates. - Small‑cell lung cancer: incorporated into combination chemotherapy for better outcomes.

Oxaliplatin may elicit a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Diarrhoea: loose stools that may require supportive care. - Fatigue: generalized tiredness during treatment cycles. - Thrombocytopenia: reduced platelet count, increasing bleeding risk.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis or bronchospasm. - Acute neurotoxicity: sudden onset of muscle cramps or spasms. - Hematologic toxicity: neutropenia or anemia requiring intervention. - Hepatotoxicity: elevated liver enzymes indicating liver stress. - Cardiotoxicity: rare arrhythmias or chest discomfort. - Renal impairment: decreased kidney function in susceptible patients.

When using Oxaliplatin, clinicians should assess patient suitability and monitor for adverse events throughout therapy.

- Renal function: evaluate baseline creatinine and adjust dosing if impaired. - Hepatic function: monitor liver enzymes before and during treatment. - Neuropathy risk: assess pre‑existing peripheral neuropathy and adjust therapy as needed. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with obstetric specialist. - Store at ambient temperature: keep in original container, protect from moisture and light.

Oxaliplatin may interact with other medicines, altering efficacy or safety. Proper review of concomitant drugs is essential.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., cisplatin, aminoglycosides): increase risk of kidney injury. - Anticoagulants (warfarin, DOACs): heightened bleeding risk due to thrombocytopenia.

Moderate Interactions (Monitor Closely): - Antiemetics (5‑HT3 antagonists): may require dose adjustment of anti‑emetic regimen. - Immunosuppressants (steroids, azathioprine): potential additive bone‑marrow suppression. - Radiotherapy: combined neurotoxicity risk, especially with peripheral nerve exposure. - CYP450 inducers/inhibitors: may modestly affect plasma levels, requiring observation. - Herbal supplements (e.g., St. John’s wort): possible alteration of drug metabolism.